Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 21;9(3):768. doi: 10.3390/cells9030768

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of anti-CD38 therapy on immune cell levels in MM. Anti-CD38 monoclonal antibodies (anti-CD38 mAb) have shown a cytotoxic effect on MM plasma cells (PC) even in the presence of protective bone marrow stromal cells, through CDC (complement-dependent cytotoxicity), ADCC (antibody-dependent cellular cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), and apoptosis after cross-linking. Anti-CD38 mAb increased the frequency, clonality and function of T-helper (T_h) and T-cytotoxic (T_C) cells, and CD38^low NK cells, while depleting CD38^high NK and CD38-expressing T-reg (T_R) suppressor cells.